Sagnik Chatterjee

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (6)

• Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
  Journal of Medical Economics 2023 DOI: 10.1080/13696998.2023.2196922
  +Save
• Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia
  Expert Review of Pharmacoeconomics & Outcomes Research 2023 DOI: 10.1080/14737167.2023.2211270
  +Save
• The Burden of Cervical Conization in Privately Insured Young and Mid-Adult Women in the United States
  Vaccines 2023 DOI: 10.3390/vaccines11040804
  +Save
• A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab
  Current Medical Research and Opinion 2022 DOI: 10.1080/03007995.2022.2105072
  +Save
• Characteristics, treatment patterns, healthcare resource use, and costs among pediatric patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas: a retrospective database analysis of a Medicaid population
  Current Medical Research and Opinion 2021 DOI: 10.1080/03007995.2021.1940907
  +Save
• <p>Treatment, Resource Use and Costs Among Pediatric Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas</p>
  Pediatric Health, Medicine and Therapeutics 2020 DOI: 10.2147/phmt.s265690
  +Save